Til innhold
Kristin Cardo
News archive
Contact
Svenska
Products
Consumer Health
Prescription Medicines
Medical Nutrition
Protein
Phenylketonuria
Maple Syrup Urine Disease (MSUD)
Tyrosinemia (TYR)
Homocystinuria
Methylmalonic & Propionic Acidaemia MMA/PA
Glutaric Aciduria (GA1)
Isovaleric Acidaemia
Urea Cycle Disorders (UCD)
Glycogen Storage Disease
Fat Metabolism
Renal
Ketogenic Diet
Low Protein Foods
Nutritional Support
Antibiotics
Supporting Initiatives
Lighter Together
In Good Company
MyControl
Partnering
Nordic Leader
In-licensing and Distribution
Out-licensing
M&A and Joint Ventures
Partners
Investors
Share
Reports and Presentations
Shareholders
Financial Calendar
Equity Research
General Meeting
Registrar
Prospectus 2020
Offer regarding Sensidose
About us
Quality
Life at Navamedic
Vacant Positions
Management Team
Board of Directors
Contact
Corporate Governance
Articles of association
EFPIA Disclosure Code
Sustainability
Products
Consumer Health
Prescription Medicines
Medical Nutrition
Protein
Phenylketonuria
Maple Syrup Urine Disease (MSUD)
Tyrosinemia (TYR)
Homocystinuria
Methylmalonic & Propionic Acidaemia MMA/PA
Glutaric Aciduria (GA1)
Isovaleric Acidaemia
Urea Cycle Disorders (UCD)
Glycogen Storage Disease
Fat Metabolism
Renal
Ketogenic Diet
Low Protein Foods
Nutritional Support
Antibiotics
Supporting Initiatives
Lighter Together
In Good Company
MyControl
Partnering
Nordic Leader
In-licensing and Distribution
Out-licensing
M&A and Joint Ventures
Partners
Investors
Share
Reports and Presentations
Shareholders
Financial Calendar
Equity Research
General Meeting
Registrar
Prospectus 2020
Offer regarding Sensidose
About us
Quality
Life at Navamedic
Vacant Positions
Management Team
Board of Directors
Contact
Corporate Governance
Articles of association
EFPIA Disclosure Code
Sustainability
News archive
Contact
Svenska
Søk
Navamedic
Kristin Cardo
Kristin Cardo
All
(170)
Regulatory
(137)
Non regulatory
(33)
Navamedic ASA: Strong growth and important product launch in Q4 2025
Publisert: 12.02.2026
